{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-024305","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.504208+00:00","generated_at":"2026-05-26T23:26:55.781491+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Korro Bio CFO Vineet Agarwal takes temporary medical leave; CEO Ram Aiyar named interim principal financial officer","bullets":["Effective Feb 11, 2025, CFO Vineet Agarwal on temporary medical leave from Korro Bio.","CEO Ram Aiyar appointed interim principal financial officer; no additional compensation.","Oliver Dolan, SVP Finance, appointed interim principal accounting officer.","Dolan has served as SVP Finance since Jan 2024; previously at Unity Biotechnology, Haven Healthcare, Compass Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-024305","json":"https://secwatch.observer/filing/0001193125-25-024305.json","markdown":"https://secwatch.observer/filing/0001193125-25-024305.md","text":"https://secwatch.observer/filing/0001193125-25-024305.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525024305/0001193125-25-024305-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525024305/d892089d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:26:55.781491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6f0e6ecb9e","claim":"Vineet Agarwal changed role as Chief Financial Officer at Korro Bio, Inc..","evidence_excerpt":"Effective February 11, 2025, Vineet Agarwal, Chief Financial Officer (principal financial officer and principal accounting officer) of Korro Bio, Inc., or Korro, is taking a temporary medical leave of absence.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525024305/0001193125-25-024305-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"taking a temporary medical leave of absence"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"cef1a2a760","claim":"Oliver Dolan was appointed as Interim Principal Accounting Officer at Korro Bio, Inc..","evidence_excerpt":"and Mr. Oliver Dolan, Senior Vice President, Finance, to serve as Korro’s interim principal accounting officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525024305/0001193125-25-024305-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"fbc6d82706","claim":"Ram Aiyar was appointed as Interim Principal Financial Officer at Korro Bio, Inc..","evidence_excerpt":"Korro’s Board of Directors appointed Dr. Ram Aiyar, President and Chief Executive Officer (principal executive officer), to serve as Korro’s interim principal financial officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525024305/0001193125-25-024305-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Principal Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}